HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic

Reuters

2025/06/26

HOPE <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic

HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation $(TMS.AU)$.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL19345) on June 26, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2546780573"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546780573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546780573?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546780573","market":"fut","top_or_hot":-1,"title":"HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HOPE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation <a href=\"https://laohu8.com/S/TMS.AU\">$(TMS.AU)$</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRXP\">NRX Pharmaceuticals Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CL19345) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-26 20:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HOPE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation <a href=\"https://laohu8.com/S/TMS.AU\">$(TMS.AU)$</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRXP\">NRX Pharmaceuticals Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CL19345) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL8cHBcw:1","article_id":"2546780573","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546780573","pubTimestamp":1750939399,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. , has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NRXP":"NRX Pharmaceuticals Inc."},"translate_title":"NRX Pharmaceuticals子公司HOPE Therapeutics将收购Cohen and Associates Clinic 49%的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9},"content_text":"HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic\n    \n\n        HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation $(TMS.AU)$.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL19345) on June 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}